Patients with high risk multiple myeloma have shorter remission periods and reduced overall
survival. Prognostic significance of minimal residual disease negative remission is being
highlighted in many of the newer studies.
The current phase 2 study investigates the combination of carfilzomib together with
cyclophosphamide and dexamethasone in patients with high risk multiple myeloma in younger
transplant-eligible patients.